Zhigang Tian, Yongyan Chen, Bin Gao – 30 October 2012 – Natural killer (NK) cells are enriched in lymphocytes within the liver and have unique phenotypic features and functional properties, including tumor necrosis factor–related apoptosis‐inducing ligand–‐dependent cytotoxicity and specific cytokine profiles.
Xiao Qi Wang, Cindy K.Y. Cheung, Chung Mau Lo – 30 October 2012
Hung‐Chih Yang, Chi‐Ling Chen, Yueh‐Chi Shen, Cheng‐Yuan Peng, Chun‐Jen Liu, Tai‐Chung Tseng, Tung‐Hung Su, Wan‐Long Chuang, Ming‐Lung Yu, Chia‐Yen Dai, Chen‐Hua Liu, Pei‐Jer Chen, Ding‐Shinn Chen, Jia‐Horng Kao – 30 October 2012 – Precore (PC) (G1896A) and basal core promoter (BCP) (A1762T/G1764A) mutations of the hepatitis B virus (HBV) genome often emerge in chronic hepatitis B (CHB) patients. Their roles in hepatitis B e antigen (HBeAg) seroconversion induced by interferon (IFN) therapy remain controversial, partly because quantitative analysis for these mutants is lacking.
Lauren E. Holz, Joo Chun Yoon, Sukanya Raghuraman, Susan Moir, Michael C. Sneller, Barbara Rehermann – 30 October 2012
Xiaolei Shi, Viviana Moroso, Herold J. Metselaar, Jaap Kwekkeboom – 30 October 2012
Domenico Sansonno, Sabino Russi, Vincenza Conteduca, Loredana Sansonno – 30 October 2012
Carlos J. Pirola, Tomas Fernández Gianotti, Gustavo O. Castaño, Silvia Sookoian – 30 October 2012
Arthur Y. Kim, Ellen H. Nagami, Christopher E. Birch, Melinda J. Bowen, Georg M. Lauer, Barbara H. McGovern – 30 October 2012 – Acute hepatitis C virus (HCV) infection is underdiagnosed because most patients are asymptomatic. The majority of new infections occur among people who inject drugs (PWID), many of whom have a history of incarceration. In a previous pilot study, we identified symptomatic HCV cases, mainly among Caucasian inmates.
Sean R.R. Hall, Alexander Pedroza‐Gonzalez, Qiuwei Pan, Hugo W. Tilanus, Jeroen de Jonge, Gerard Wagemaker, Luc J.W. van der Laan – 30 October 2012
Austin Duffy, Julia Wilkerson, Tim F. Greten – 30 October 2012 – The presence of cirrhosis increases the potential risk of hemorrhage for patients with hepatocellular carcinoma (HCC). We evaluated the relative risk for hemorrhage in patients with HCC treated with antiangiogenic agents. We performed a systematic review and meta‐analysis of antiangiogenic studies in HCC from 1995 to 2011. For nonrandomized studies we compared bleeding risk with other HCC single‐arm studies that did not include an antiangiogenic agent.